Blincyto (blinatumomab) for injection is a bispecific CD19-directed CD3 T- cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Serious side effects of Blincyto include Cytokine Release Syndrome (CRS) and...
The third track of PEGS Europe 2023 is ‘Advancing bispecifics and combination therapy to the clinic’, which will feature a range of sessions made up of presentations, talks and posters which address translational approaches to optimising dosing, T cell engagers, novel approaches, harnessing neutrop...
This near miss is a common incident in the community practice setting given its fast pace and evolving prevalence of biosimilar usage. Biosimilars May Decrease The Cost Of Cancer Care The trajectory and rising costs of cancer care have led to significant fiscal impact. Various countries spend billi...
In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what
Harpoon Therapeutics Launches ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets Harpoon Therapeutics is seeking to develop a robust pipeline of TriTAC candidates. Harpoon Therapeutics Names Drachman as Director Harpoon is...
9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook AcronymDefinition TregRegulatory T Cells TregTetra-Ethylene Glycol TregThe Real Estate Group, Inc TregTregorrois(linguistics) TregTelecommunications Regulatory Email Grapevine ...
What is DeepSeek? Create a free Seeking Alpha account and read the latest news »Learn MoreSeeking Alpha - Power to Investors Power to Investors Follow us Download app Subscription Support: 1-347-509-6837 RSS Feed Sitemap Group Subscriptions Affiliate Program About Us Careers C...
The collaboration will combine Immatics' world-leading XPRESIDENT target discovery and T-cell receptor (TCR) capabilities with Amgen's validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs. AMGEN AND IMMATICS ENTER STRATEGIC COLLABORATION Amgen's Baa1 rat...